Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies

Publisher： John Wiley & Sons Inc

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.7, 2015-04, pp. : 997-1007

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab and irinotecan for glioblastoma

By  

PEDIATRICS INTERNATIONAL, Vol. 57, Iss. 1, 2015-02 ,pp. : 169-171

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bevacizumab‐induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab

By  

CANCER, Vol. 121, Iss. 9, 2015-05 ,pp. : 1456-1462

John Wiley & Sons Inc

Access to resources Recommend Favorite

The use of temozolomide as a radiosensitiser for the treatment of newly diagnosed glioblastoma multiforme

By  

Journal of Radiotherapy in Practice, Vol. 6, Iss. 2, 2007-06 ,pp. : 103-110

Cambridge University Press

Access to resources Recommend Favorite

Infrared Thermography in Surgery of Newly Diagnosed Glioblastoma Multiforme: A Technical Case Report

By  

Case Reports in Oncology, Vol. 10, Iss. 1, 2017-04 ,pp. : 350-355

Karger

Access to resources Recommend Favorite

FLAIR-Only Progression in Bevacizumab-Treated Relapsing Glioblastoma Does Not Predict Short Survival

By  

Oncology, Vol. 85, Iss. 3, 2013-09 ,pp. : 191-195

Karger

Access to resources Recommend Favorite